SOFT TISSUE SARCOMA

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This trial investigates whether combining two drugs, camrelizumab and famitinib, can help people with rare head and neck cancers that have spread or cannot be removed by surgery. The study includes four types of these cancers and aims to see how safe and effective the treatment i…

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to pri…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bone or soft tissue sarcoma live longer without their cancer growing. About 134 participants whose cancer has not responded to standard treatments will b…

This study tests whether a 5-day course of radiation before surgery is as safe and effective as the standard 25-day course for adults with soft tissue sarcoma. Researchers will track complication rates and whether the cancer comes back. The goal is to make treatment faster and mo…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a shorter, higher-dose radiation therapy given over one week before surgery for soft tissue sarcoma in patients aged 70+ or those 65+ who are considered fragile. The goal is to see if this approach reduces major wound complications after surgery. About 48 partici…

This study looks at whether giving patients with bone or soft tissue sarcoma a special nutritional supplement twice daily before surgery can reduce complications and help maintain muscle mass. About 100 adults scheduled for tumor removal will be randomly assigned to receive eithe…

This study is for adults with high-risk soft tissue sarcoma that can be removed by surgery. It tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy, radiation, and surgery can delay the cancer from coming back. About 50 participants will receive the …

This early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…

This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's…

This early-stage trial is testing a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcomas that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The…

This early-phase trial tests a new treatment called Attil12-T cell therapy for people with advanced soft tissue or bone sarcoma that has spread or cannot be removed. The therapy uses a patient's own immune cells, modified to target and attack the tumor. The main goals are to find…

This phase 2 trial tests whether adding envafolimab (an immunotherapy) to standard chemotherapy (doxorubicin and ifosfamide) can improve outcomes for people with advanced soft tissue sarcoma who haven't had prior treatment. About 25 adults will receive the combination every 3 wee…

This study tests whether giving targeted radiation to cancer that has spread (metastasized) can help children, teens, and young adults with sarcoma live longer. About 70 participants with soft tissue or bone sarcoma will receive consolidative radiation therapy to their metastatic…

This study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced soft-tissue sarcoma that has spread. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and see if the treatment slows tumor grow…

This study is testing whether a shorter course of proton therapy (just five treatments) before surgery for soft tissue sarcoma is safe and effective. Researchers will track wound healing, side effects, and quality of life in 40 adult patients over two years. The goal is to see if…

This Phase 3 trial is testing whether adding four cycles of chemotherapy (doxorubicin-based) to standard surgery and radiation can improve outcomes for people with high-risk soft tissue sarcoma. The study will enroll 600 participants, with 250 high-risk patients randomly assigned…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests whether adding an experimental immunotherapy drug called retifanlimab to standard chemotherapy (gemcitabine and docetaxel) is safe and effective for people with advanced soft tissue sarcoma that cannot be removed by surgery. About 98 participants will receive the…

This phase 2 trial tests whether two drugs, cadonilimab and anlotinib, can help people with advanced or metastatic soft tissue sarcoma whose first treatment stopped working. About 27 adults will receive the combination to see if it slows tumor growth. The study is currently recru…

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This phase 2 trial tests whether a shorter course (2-3 weeks) of proton or carbon ion radiation before surgery for extremity soft tissue sarcoma is safe and feasible. The main goal is to see if it reduces wound healing problems after surgery. The study enrolls 42 adults with rese…

This study tests a 5-day course of radiation given before surgery for soft tissue sarcoma in the arms, legs, or trunk. The goal is to see if this shorter treatment is safe and effective at controlling the cancer while preserving more healthy tissue. About 40 adults will receive r…

This phase II trial is testing whether a special type of radiation therapy (SFRT) given before surgery can improve outcomes for people with large soft tissue sarcomas (at least 5 cm) in the limbs or trunk. About 22 adults will receive 5 doses of SFRT, then have surgery about a we…

This phase II trial compares the chemotherapy drugs trabectedin and gemcitabine in 100 people with advanced leiomyosarcoma that has worsened after initial treatment. The study aims to see which drug better delays cancer progression. It also includes an observational group for tho…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This study tests an experimental drug, tigilanol tiglate, injected directly into tumors in people with advanced soft tissue sarcoma that has spread. The goal is to see if it can shrink or destroy treated tumors. About 40 adults with tumors on the arms, legs, or body wall will tak…

This expanded access program provides DNG64-CAR-V, a gene therapy, to patients with advanced pancreatic cancer, sarcoma, or breast cancer who have exhausted standard treatments. The therapy is given intravenously or directly into tumors, alone or with other cancer drugs. Early st…

This study tests whether a special vacuum dressing placed on the surgical wound can reduce complications like infection and re-operation in people with soft-tissue sarcoma of the leg who had radiation before surgery. About 291 adults will be randomly assigned to get either the va…

This phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy …

This pilot study is testing whether high-intensity focused ultrasound (HIFU) can safely destroy soft tissue sarcoma and small desmoid tumors without surgery. About 10-16 adults with these tumors will receive a single outpatient treatment using a CE-approved device. The goal is to…

This study compares a shorter, more intense course of radiation (5 sessions) to the standard longer course (25 sessions) given before surgery for soft tissue sarcoma. The goal is to see if the shorter schedule is safe and effective at killing tumor cells. Thirty adults with sarco…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This study tests a new combination of drugs for people with advanced bone or soft tissue sarcomas that have worsened after initial treatment. The combo includes a safer form of paclitaxel, standard chemotherapy, and a targeted therapy chosen based on tumor type. About 46 particip…

This trial is testing a new type of radiation therapy given before surgery for retroperitoneal sarcoma, a rare cancer in the abdomen. The radiation is delivered in just five high-dose sessions, targeting the tumor and any nearby nodules. The goal is to see if this approach reduce…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…

This early-phase study tests a technique called in vivo lung perfusion (IVLP) that delivers chemotherapy directly into the lung during surgery to remove sarcoma tumors that have spread to the lungs. The goal is to kill any tiny cancer cells left behind that could cause the cancer…

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study compares whole-body MRI, PET/MR, and PET/CT scans to see which is best at finding tumors in children and young adults with solid tumors, lymphoma, or osteosarcoma. Researchers will check how many tumors each scan detects and measure their metabolic activity. The goal i…

This study tests whether a dye called indocyanine green can help surgeons see if any cancer remains after removing a sarcoma. About 50 adults with bone or soft tissue sarcoma will receive the dye during surgery, and the surgeon will check for glowing areas that might indicate lef…

This study is testing whether a special PET/CT scan using a tracer called 68Ga-DOTATATE can improve the detection of soft tissue sarcomas. About 30 adults with this cancer will receive the scan to see if it highlights tumors better than standard imaging. The goal is to determine …

This study tests whether a tailored exercise program before standard surgery and radiotherapy helps people with soft tissue sarcoma recover better. Thirty adults with deep soft tissue sarcoma of the lower leg will either receive the prehabilitation program or standard care. The s…

This study looks at whether giving sarcoma patients early access to mental healthcare before and after surgery can help with depression, anxiety, and quality of life. About 60 adults with bone or soft tissue sarcoma who are scheduled for surgery at Memorial Sloan Kettering will t…

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

This study tests whether doing a short exercise routine just before radiation therapy can improve arm or leg function and reduce wound problems after surgery for soft tissue sarcoma. About 24 adults with sarcoma in an arm or leg will take part. They will use rubber bands or a han…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…

This study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This small pilot study is testing whether contrast-enhanced ultrasound (CEUS) can help doctors monitor how soft tissue sarcoma responds to radiation therapy. Ten adults scheduled for radiation will get CEUS scans before, during, and after treatment. The goal is to see if CEUS ima…

This study is testing whether a special MRI scan and blood tests can predict if soft-tissue sarcoma will spread to other parts of the body. Researchers will look at markers of low oxygen levels in the tumor and blood. The goal is to help doctors personalize treatment for each pat…

This study looks at how people move and feel after surgery for bone or soft tissue sarcoma in the leg. Researchers will measure physical function, quality of life, and activity levels in 60 adults who had limb-saving surgery at least one year ago. The goal is to learn more about …

This study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…

This study looks at how people feel about their bodies and how well they can move after surgery for soft tissue sarcoma in their arms or legs. Researchers will ask 150 patients to fill out questionnaires and do physical tests like walking and strength checks. The goal is to learn…

This study collects tumor and blood samples from 1,000 children with solid cancers like neuroblastoma and sarcoma. Researchers will analyze the genetic makeup and immune response of these tumors to better understand how they grow and resist treatment. The goal is to gather knowle…

This study is testing whether a smartphone app can help track recovery in 800 sarcoma patients after surgery. Participants will fill out questionnaires and have their phone passively monitor steps, stairs, and other mobility data for up to a year. The goal is to see if this digit…

This study is developing a new way to deliver chemotherapy directly to sarcoma tumors using tiny particles activated by light through an optic fiber. Researchers will test these nanoparticles on cells and tissue samples from 30 patients with bone or soft tissue sarcomas. The goal…